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Abstract Since the beginning of the last decade,
exosomes have been of increased interest in the science
community. Exosomes represent a new kind of long dis-
tance transfer of biological molecules among cells. This
review provides a comprehensive overview about the
construction of exosomes, their targeting and their fusion
mechanisms to the recipient cells. Complementarily, the
current state of research regarding the cargo of exosomes
is discussed. A particular focus was placed on the role of
exosomes in the central nervous system. An increasing
number of physiological processes in the brain could be
associated with exosomes. In this context, it is becoming
more apparent that exosomes are involved in several
neurological and specifically neurodegenerative diseases.
The treatment of these kinds of diseases is often difficult
not least because of the blood-brain barrier. Exosomes are
very stable, can pass the blood-brain barrier and, there-
fore, reveal bright perspectives towards diagnosis and
therapeutic treatments. A prerequisite for clinical applica-
tions is a standardised approach. Features necessary for a
standardised diagnosis using exosomes are discussed. In
therapeutic terms, exosomes represent a promising drug
delivery system able to pass the blood-brain barrier. One
option to overcome the disadvantages potentially associ-
ated with the use of endogenous exosomes is the design
of artificial exosomes. The artificial exosomes with a
clearly defined therapeutic active cargo and surface mark-
er ensuring the specific targeting to the recipient cells is
proposed as a promising approach.
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Introduction to Small Vesicles
Over the last two decades, the intercellular communication
became an intriguing research topic not solely in basic science
but also in applied research. Besides short distance intercellu-
lar communication systems such as gap junctions and ligand-
receptor interactions (e.g. cytokines), there do exist also long
distance intercellular communication systems. These are ei-
ther based on single molecules, like hormones, or on specific
membrane-based structures, which can contain multiple mol-
ecules. One example for such a membrane-based structure is
tunnelling nanotubes (TNTs), which are thin (50–700 nm) and
up to 100 μm long actin containing tubes formed from the
plasma membrane [1]. The TNTs can connect different kinds
of cells and carry components of the cytoplasm between these
cells such as vesicles and organelles [2]. TNTs may be in-
volved in cell-to-cell communication [3], transfer of nucleic
acids [2] and the spread of pathogens or toxins such as HIV
and prions [4, 5]. Another example of membrane-based struc-
tures used for long distance intercellular communication is
small vesicles. Small vesicles can mediate a cell-to-cell com-
munication over long distances. They are suggested to control
fundamental cellular responses such as intercellular signalling
and immune reactions [6]. This is supported by the facts that
small vesicles are relatively stable structures and the content of
the vesicles is protected from degradation processes. For these
reasons, among clinicians, the usage of small vesicles, namely
exosomes, is widely discussed as a diagnostic tool and/or a
potentially well-reputed therapeutic solution towards lot of
diseases such as cancer or neurodegenerative diseases.
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From the early stages of extracellular vesicle (EV) research,
there was no clear definition regarding the identification and
origin of small vesicles. It is unclear in some of the past studies
what kind of vesicles they have applied for the experiments.
This ambiguity is due to the technical limitations in the detec-
tion of such small-sized vesicles, the lack of a clear definition
of each class and the impure isolates. Subsequently, it is not
clear to which class of vesicles the presented data are corre-
lated [7]. In the last few years, there was a major attempt to
classify and identify these EVs and their cargo. Meanwhile,
some general databases such as Exocarta (http://www.
exocarta.org/) and Vesiclepedia (http://microvesicles.org/) are
established to document data internationally and share this
data for further investigations. However, improved methods
are needed to isolate pure classes of extracellular vesicles.
Also an international agreement on naming these vesicles
can unify obtained information and help to enlighten on
their biological function. Consequently, these improvements
Fig. 1 Formation and release of
exosomes. a Exosome formation
initiates by inward budding of
plasmamembrane to formMVBs.
By formation of MVBs, receptors
on the surface of plasma
membrane locate inside the
MVBs (1–3). Inward budding of
MVBs results in the formation of
internal vesicles inside the MVBs
(4–5). By this stage, internal
vesicles carry components from
inside the cell such as cytosolic
proteins or RNAs. Designated
targeting molecules such as
receptors are located on the outer
surface of these vesicles similar to
their location on the plasma
membrane of the cell. b There are
two possible destinations for the
MVBs, which contain the internal
vesicles. Either they are digested
by lysosomes (6) or the MVB
membrane fuses with the plasma
membrane to release the internal
vesicles now called exosomes (7).
After reaching to their target cell,
exosomes deliver their cargo
either by adhesion via members
of integrin family (8), via receptor
ligand interaction (9) and/or via
internalisation by endocytosis
(10). c Exosomes deliver their
cargo to the target cell either by
fusion (left part) or hemifusion
(right part). Fusion: the
membrane of exosome and the
target cell merge and result in an
interconnected structure.
Hemifusion: after releasing of
cargo, the exosome membrane
disconnected again from the
plasma membrane of the target
cell. MVB multivesicular body
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will facilitate scientists and clinicians to apply these vesicles
for diagnoses or disease treatments.
In this review, we discuss the known characteristics of
exosomes and try to clarify the cargo packaging and vesicle
targeting. Furthermore, we focus on their potential roles in the
treatment of neurological diseases such as multiple sclerosis
(MS).
EVs are small vesicles, which are secreted by prokaryotic
and eukaryotic cells [8, 9]. Here, we distinguish between three
classes of EVs, namely apoptotic bodies (ABs), microvesicles
(MVs) and exosomes. It is known that most of the cells such
as reticulocytes, dendritic cells (DCs), B cells, T cells, mast
cells, platelets, epithelial cells, neurons, oligodendrocytes,
Schwann cells and tumour cells are able to release exosomes
[10–13]. However, the majority of exosomes detected circu-
lating in vivo are platelet derived. The normal ratio of
microvesicle found in blood plasma is nearly 80 % platelet
derived, 10% endothelial derived and 10% leukocyte derived
[11, 12]. Exosomes are present in physiological fluids such as
plasma, lymph liquid, malignant pleural effusion, amniotic
liquid, breast milk, semen, saliva and urine [14–18]. The
conventional pathway of forming exosomes starts by inward
budding of plasma membrane into forming multivesicular
bodies (MVBs) (Fig. 1a 1–3) [19]. Alternatively, MVBs can
be constituted from the trans-Golgi network [20].Within these
MVBs, exosomes can be formed by inward budding (Fig. 1a
4–5) and, subsequently, can be released by fusion of MVBs to
the plasma membrane (Fig. 1b 7) [21]. It is proposed by van
der Pol et al. that there is also a direct formation and release of
exosomes from the plasma membrane. These vesicles also
carry markers assigned to exosomes such as CD63 and
CD81 and look identical to exosomes secreted by fusion of
MVBs with the plasma membrane [19] (Table 1). In order to
have a common understanding, in this review, we have de-
fined ABs, MV and exosomes with the following
characteristics:
& ABs are the result of apoptosis. They are heterogeneous in
shape and contain materials such as DNA, RNA, histones
and signalling molecules [19]. One signalling molecule
for macrophages to remove ABs is the vitronectin recep-
tor, which consists of two components (integrin α-V and
integrin β-3 (CD61)) [22]. ABs originate from the plasma
membrane, can be released from all cell types and are
about 1–5 μm in size.
& MVs with the size of 20 nm–1 μm are formed due to
blebbing with incorporation of cytosolic proteins. In con-
trast to ABs, the shape of MVs is homogenous. They
originate from the plasma membrane and are observed in
most cell types.
& Exosomes are vesicles with the size of 50–100 nm ob-
served in most cell types similar toMVs with a difference:
Instead of originating directly from the plasma membrane,
they are generated by inward budding into MVBs. Fusion
of these MVBs to the plasma membrane results in the
release of the exosomes [19, 23].
Although MVBs and MVs originate directly from the
plasma membrane, the machineries involved in the formation
and release of each are likely to differ [13]. Overall, MVs and
exosomes are two separate classes of vesicles, which might
overlap in size. In practical terms, they are indistinguishable
from exosome. Therefore, MV in some studies is used as a
general term for all small vesicles/particles which includes
exosomes but not ABs [19]. Exosomes andMVs are generally
smaller than ABs and, unlike them, contain rarely any DNA
[11]. Most of the published data are from impure preparations
of exosomes. The common protocol for exosome preparation
is differential centrifugation to pellet the exosomes based on
their size. However, by this method, the pellet includes also
other vesicles in the size of exosomes such as MVs and large
protein aggregates [7, 24]. It was observed that exosomes get
released from most cells constantly; however, the level in-
creases in the plasma of patients with inflammation, cell
injury, thrombosis and platelet activation [11, 25, 26].
Biogenesis and Targeting of Exosomes
Exosomes are formed by inward budding. Therefore, the
orientation of proteins and lipids of the exosome membrane
is equivalent to the plasma membrane of the parental cell
(Fig. 1b 7) [27]. MVBs are late endosomes, which are refined
by early endosome maturation. This maturation results in
gradual changes in content and composition of the membrane
[28]. The machinery involved in the formation of MVBs is
relevant to exosome production. It is suggested for mamma-
lian cells that phosphatidylinositol-3 kinase activity is re-
quired for both the formation of MVBs and the formation of
Table 1 Vesicle formation
Extracellular vesicle Observed by Size Origin Formation due by
ABs Apoptotic cells 1–5 μm Plasma membrane Apoptosis
MVs Most of the cells 0.2–1 μm Plasma membrane Plasma membrane blebbing
Exosomes Most of the cells 50–100 nm MVBs Inward budding
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exosomes (Fig. 1b 7) [27, 29]. Fernandez-Borja et al. showed
that the inhibition of phosphatidylinositol-3 kinase results in
swelling of several endocytic compartments and inhibition of
MVB biogenesis [29].
There are two possible fates for the MVBs: Either they are
designated to fuse with the plasma membrane (Fig. 1b 7), or
alternatively, they fuse with a lysosome followed by digestion
of the cargo (Fig. 1b 6) [13]. It was reported that cholesterol-
rich MVBs are prone to release exosome and cholesterol-poor
MVB are targeted to lysosomal digestion [30]. Another study
showed that incorporation of membrane proteins such as
growth factor receptors designates MVB to lysosomal degra-
dation [27]. The molecular machinery involved in the biogen-
esis of exosomes can be dependent on or independent from
endosomal-sorting complex responsible for transport (ESCAR
T). The ESCART-dependent system is associated with acces-
sory proteins such as programmed cell death 6 interacting
protein (Pdcd6ip; also known as ALG2-interacting protein X
(Alix)) and vacuolar protein sorting 4 (VPS4), which are used
as exosome markers in many studies [13]. Alternatively, in the
presence of sphingomyelinase, the exosome biogenesis might
be independent from ESCART. Trajkovic et al. showed by
inhibition of sphingomyelinase that the release of exosomes is
significantly reduced [31]. Simons et al. showed that MVB
formation can even be independent from ESCART and
sphingomyelinase. By their results, tetraspanin proteins
enriched in MVBs can play a major role in the formation of
exosomes [32]. In addition, domains such as endosome-like
domains, which are the site of endosomal protein binding in
plasmamembranes, serve also as a site for exosome biogenesis.
These are the same sites wherefrom immunodeficiency virus
(HIV) particles bud [33]; thereby, a number of cell-type-specific
pathways bringing further insights into the classifications of
EVs are reported [32, 34].
– Elements designating the fate of MVBs





MVBs designated to exocytosis release the exosomes into
the extracellular space by fusion with the plasma membrane.
The release of exosomes can be constitutive or inducible
depending on the cell type and the state of cell activation
[17, 35]. For instance, immature DCs and epithelial cells
release exosomes in a constitutive manner [36]. Another study
has indicated that members of Rab family are involved in
classical intracellular trafficking and in fusion of cellular
compartment. It was also observed that a subset of this family,
such as Rab27a and Rab27b, is involved in the secretion of
exosomes [37]. For the last step of MVB fusion with the
plasma membrane, it is also suggested that soluble N-
ethylmaleimide-sensitive factor attachment receptor
(SNARE) proteins play a crucial role [38].
It was observed that the protein content detected on the
surface of exosome is significantly different from the ones on
the plasma membrane. As an example, purified exosomes do
not contain transferrin receptors (TfRs, a marker for plasma
membrane and endosomes) [39]. The released exosomes are
featured to reach their target cell to introduce the cargo. The
targeting process is shown to be selective. Studies provided
lines of evidence that although platelet-derived exosomes
attach to bothmonocytes and neutrophils, transcription factors
carried by these exosomes only get transferred to monocytes
[40]. Another study showed that isolated B cell-derived
exosomes specifically bind to follicular DCs [41]. It was
demonstrated that the subsequent fusion is likely to be regu-
lated by factors such as Ca2+ [42] and/or syntaxin-7 [43].
Although the efficiency of exosome transfer between cells is
unknown, there are direct lines of evidence of exosome fu-
sions to recipient cells. Using a fluorogenic dequenching
assay with lipophilic dye R18-labelled exosomes,
Montecalvo et al. have demonstrated that exosomes are capa-
ble of delivering their intraluminal cargo into the cytosol of the
recipient cell [44]. The interactions of exosomes and target
cells are target cell dependent and categorised as follows:
& Fusion to the target cell, such as adhesion via members of
the integrin family or such as fusion of exosomes to
monocyte with mediation of calcium and annexin V [41,
45, 46] (Fig. 1b 8).
& Receptor ligand interaction, such as antigen presentation
and transfer of exosomes to B cells by mediation of
complement receptor type 2 (Cr2 or CD21) [39, 45]
(Fig. 1b 9).
& Internalisation by endocytosis, such as endocytosis of
exosomes by DCs [10, 44, 47] (Fig. 1b 10).
It was observed that the efficiency of the fusion between
exosome and recipient cell is also under control of environ-
mental conditions as well as the state of the recipient cell such
as maturation. As an example, fusion occurs more efficiently
between exosomes and cells under acidic conditions [47, 48].
This consequently suggests a more frequent fusion within the
tumour mass, which normally is more acidic, compared to the
surrounding normal tissue. Additionally, Morelli et al. report-
ed that the “exosome take-up ability” of BALB/c bone mar-
row–DCs decreases by the maturation of DCs, and conse-
quently, immature DCs have a higher capacity to capture
exosomes [49]. The fusion of exosomes to the target cell is,
for at least a percentage of exosomes, not a complete fusion
but just a hemifusion sufficient to release their content to the
recipient cell (Fig. 1c) [44].
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– Fusion of exosomes to the target cell
& Via internalization by endocytosis
& Via members of the integrin family
& Via receptor ligand interaction
Cargo of Exosomes
Initially, it was assumed that the content of exosomes is
random due to the engulfed part of the cytoplasm packaged
by the membrane blebbing [50]. Later, it was observed that the
content of exosomes released by mesenchymal stromal cells
(MSC) differs from their parental cells, probably caused by
selective packaging. Although the sorting mechanisms of
nucleic acids and proteins are poorly understood, there are
some suggestions for sorting proteins inside exosomes, such
as sorting via ESCART, via lipid and/or protein affinity or via
sorting by protein incorporation into detergent-resistant pro-
tein complexes [17]. It is mentioned that exosomes contain
some common and some cell-type-specific proteins [28].
Thery et al. reported that exosomes do not contain proteins
that originated from the nucleus, mitochondrion, endoplasmic
reticulum or Golgi apparatus. Instead, proteins identified in
exosomes were also observed in the cytosol and plasma
membrane [36]. In contrast, a subsequent study by Record
et al. reported that exosomal proteins could also originate from
the endocytotic compartment, Golgi and nucleus, but rarely
from the endoplasmic reticulum or mitochondria [17].
RNAs detected in exosomes of MSCs consist of mainly
messenger RNA (mRNA) and microRNA (miRNA). No track
of 18S or 28S ribosomal RNAwas detected. Indeed, in these
exosomes, the portion of mRNAs is relatively small, while
majority of small RNAs as well as miRNAs in precursor form
were observed [51]. This observation suggests that the pack-
aging of nucleic acid is not a random encasing of cytoplasmic
content. Furthermore, there are essential differences between
mRNA transcripts in parental cells compared to mRNA tran-
scripts detected in exosomes, namely mRNA might be
enriched in exosomes but not detectable in parental cells
[10]. Such a selection was also observed for a number of
detected miRNAs, which are assumed to be exclusively
packed to exosomes [26]. Baglio et al. have observed that
some miRNAs were present in both exosomes and parental
cells. Nonetheless, some miRNAs appeared to be selectively
sorted to exosomes and are not detectable in the parental cells.
This observation supports the existence of control mecha-
nisms for selective packaging of miRNAs for at least MSCs
[26]. Likewise in AZ-P7a cells (a metastatic gastric cancer cell
line), an enrichment of let-7 miRNA family members (tumour
suppressor genes that target oncogenes) in exosomes was
observed. The exosomal release of let-7 miRNAs into the
extracellular environment maintained the oncogenesis and
invasiveness of AZ-P7a cells by at least partially neutralising
the inhibitory effects of let-7 miRNAs on their targeting
oncogenes such as RAS and HMGA2 [10, 12, 52]. In another
study, it was shown that the enrichment of miRNAs in the
exosomes derived from DCs is selective as some miRNAs are
detected in parental cells but not in the exosomes and vice
versa [44].
As a matter of fact, miRNAs are delivered to distant cells
by either miRNA containing exosomes or via free miRNA-
molecules bound to Argonaute 2 (Ago2). It was shown that
Ago2 is not only bound to free extracellular miRNAs but also
to miRNAs within exosomes and other membrane-derived
vesicles [12]. In most cases, miRNAwas found single strand-
ed in exosomes, yet precursor hairpin miRNAs were also
detected [12, 51]. It is hitherto not clear if Ago2 is necessary
for miRNA export [12].
The regulatory functions of miRNAs are accomplished
through the RNA-induced silencing complex (RISC) [53]. It
is believed that the mature miRNA not connected to RISC is
not functional. Pre-miRNA can be loadedwith RISC followed
by cleavage into functionally mature RISC-loaded miRNA.
The favoured secretion of pre-miRNA into exosomes suggests
an important physiological role after being taken up by target
cells and also supports the thesis that the content of exosomes
is not just random [51].
Notwithstanding, miRNAs isolated from plasma
exosomes, which are mostly platelet derived, has a significant
different composition compared to platelets and peripheral
blood mononuclear cells. As a consequence, many miRNAs
are uniquely present in exosomes isolated from plasma [11].
The number and content of exosomes consistently vary based
on the microenvironmental conditions of the cells and, partic-
ularly, if cells are subjected to stress factors [26]. It is shown
that the miRNA content of exosomes in the plasma is different
between normal and tumour-induced tissues [11]. Breast can-
cer cells produce exosomes with a changed pattern of miRNA
[54]. Another example is the stimulated release of exosomes
by increase of intracellular Ca2+ in neutrophils [38, 55]. Such
stimulations also affect the content of exosomes. Finally, the
miRNA content of exosomes also depends on the maturation
state of the parental cell. The miRNA content of exosomes
derived from mature DCs, which promote immunity, and the
miRNA content of exosomes derived from immature DCs,
which downregulate T cell responses, were observed to be
significantly different. However, there is no significant differ-
ence in the amount of miRNA between exosomes derived
from mature DC and immature DC [44]. It is important to
mention that ABs, MVs and exosomes contain fundamentally
different RNA profiles. For instance, MVs isolated from cell
culture often do not contain a considerable amount of RNA.
Ribosomal RNA is primarily found in ABs [56]. A selective
loading is not only observed for protein and RNA but also for
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other types of molecules packed into exosomes. Regarding
DNA as a content of exosomes, there exists a disagreement.
One study announced that exosomes contain no DNA [10];
later, it was observed that astrocyte-derived exosomes might
contain mitochondrial DNA [57, 58]. This discrepancy in the
reported data demonstrates the need of further investigations
in this field.
To sum up, exosomes play an important role in long
distance cell-cell communication. They mainly contain a se-
lection of different physiologically active proteins, miRNAs
and mRNAs. Based on the parental cell status and/or the
microenvironmental conditions, the content and the number
of exosomes are varying.
Detection of Exosomes
Although exosomes originated from a parental cell, their
composition is to some extent different from the parental cell
as mentioned above. Many plasma membrane proteins are
depleted, and therefore, exosomes are distinguishable from
shed plasma membranes [28]. Nevertheless, there are a num-
ber of proposed exosome reference markers such as
lysosomal-associated membrane protein 2 (Lamp-2) and Rab
5B, which is a member of the RAS oncogene family [47].
Also, proteins such as Pdcd6ip, tumour susceptibility gene
101 (TSG101), tetraspanin proteins resulting from exosome
formation in MVBs (CD9, CD63, CD81 and CD82) and
proteins enabling intracellular membrane fusion and transpor-
tation [36] are often used as markers to detect and identify
exosomes [23]. There are kits to detect exosomes in vivo
available such as Exosomal Cyto-Tracer (The lentivector
based Cyto-Tracer (Biocat GmbH) expresses the tetraspanin
CD63, CD9 or CD8, which are fused to GFP or RFP. In this
way, exosomes are marked and long-term and in-depth exper-
imentation is enabled). However, these proposed reference
markers are also present in MVs and ABs [56]. Therefore,
they are not sufficient to establish a method to isolate/detect a
pure population of exosomes. As a consequence, there is a
need of improved techniques to detect exosomes in vivo and
in vitro in a more specific manner.
Exosomes and the Central Nervous System
Exosomes represent a major step in the diagnosis and treat-
ment of many neurological diseases, such as Alzheimer’s
disease (AD) and MS. In this context, the ability of exosomes
to cross the blood-brain barrier (BBB) [59] is important in two
aspects: First, considering the central nervous system (CNS) is
highly protected and consequently not easily accessible, in-
formation regarding the cells in the CNS can be obtained via
exosomes that passed through the BBB. Second, exosomes
not only cross the BBB from the brain towards the blood and
vice versa, but also can target a specific cell type and deliver
the protein or nucleic acid content into their target cell [60].
Therefore, an exosomal delivery system potentially can trans-
port pharmaceutically active substances and genetic materials
across the BBB into the CNS. In order to use this kind of
delivery system more efficiently, it is beneficial to know the
cell-specific functions of exosomes as well as their biological
roles in the brain. It is indicated that exosomes are linked to a
number of different biological processes in the CNS, such as
their crucial role in synaptic plasticity, regulation of myelin
membrane biogenesis, as well as transfer of proteins or nucleic
acid locally to highly polarised structures like neurons [6].
Among other things, it is proposed that exosomes play a
role in synaptic plasticity. This could be achieved by the
delivery of specific sets of proteins, mRNAs and miRNAs
from the postsynaptic to the presynaptic terminal via
exosomes [61]. Also the transport from presynaptic to post-
synaptic terminal via exosomes was observed for synaptotag-
min 4 (Syt4, a membrane-trafficking protein). Korkut et al.
have shown that the entire pool of postsynaptic Syt4 is pro-
vided from presynaptic exosomes. Considering Syt4 is essen-
tial for retrograde signalling, the Syt4 exosomal transport
supports the presynaptic control of retrograde signals [62].
The role of exosomes in synaptic plasticity is also supported
by the detection of MVBs in neurons [63] and the fact that the
MVB fusion to plasma membrane is linked to synaptic activ-
ity [64] (Fig. 2a).
The regulatory function of exosomes involved in myelin
membrane biogenesis was observed between glial cells and
axons (Fig. 2b). It is described that exosomes on the one hand
contribute to eliminate overproduced myelin membranes [65]
and, on the other hand, participate in myelin membrane bio-
genesis [66].
As a matter of fact, most if not all of the cell types in the
CNS release exosomes. The exosome cargos in the CNS vary
based on the cell of origin as well as the cells’ health/stress/
disease state and can be changed in response to environmental
situation [67]. Consequently, in the CNS, exosomes are in-
volved in different procedures such as communication and
regulation. Their role in communication is supported by the
facts that (i) exosomes are intercellular vehicles for RNA
transfer within the CNS [10] and (ii) exosomes also contain
abundant proteins involved in cell-cell communications such
as heat shock proteins and tetraspanins [35, 61, 65].
Exosomes Derived from Different Cell Types in the CNS
Here, we introduce several known cell-type-specific
exosomes such as neuronal, glial (microglia and macroglia)
and mast cell-derived exosomes. Neurons as well as most glial
cell types release exosomes. Besides neuron-specific
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Fig. 2 Active role of exosomes in the central nervous system. a
Exosomes play a crucial role in synaptic plasticity. Syt4 is a membrane-
trafficking protein and is essential for retrograde signalling. It was
observed that exosome containing Syt4 (demonstrated by brown circles,
indicated with dark arrows heads) are released from presynaptic terminal
and thereby the entire pool of Syt4 in postsynaptic terminal is provided by
exosomes from the presynaptic terminal. The yellow arrow presents the
release of neurotransmitters (yellow triple-circle shapes) from presynaptic
terminal and binding of them to neurotransmitter receptors (orange two-
circle shapes). Release of neurotransmitters allows entry of Ca2+ to the
presynaptic terminal and activates fusion of exosome-containing MVBs
to the plasma membrane. b In the CNS, different cell types such
as neurons, oligodendrocytes and microglia release exosomes
(exosomes of each cell type are performed by small circles coloured in
parental cell colour). Released exosomes reach different cell type in
distance and deliver their cargo to other cells. Therefore, cells in the
CNS can communicate with each other and help to regulate their
function. c Exosomes derived from resident cells in the CNS can pass
through the BBB. Mast cell-derived exosomes (dark blue circles) can
pass through the BBB and are able to activate B and T cells or induces
DCs to become efficient antigen-presenting cells. B cell-derived
exosomes, in turn, can stimulate T cells or transfer MHC class II
proteins to the surface of follicular DCs, which do not express these
molecules
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components, neuron-derived exosomes largely resemble non-
neuron-derived ones [61] and mediate a regulatory as well as
communicative function [68]. Neurotransmitters released
from the pre- to postsynaptic terminal allow Ca2+ entry to
the neuron through synaptic receptors (Fig. 2a). This activates
MVB fusion to the plasma membrane followed by the release
of exosomes. Thus, more active neurons within a circuit are
able to release more exosomes than less active or immature
neurons [69, 70]. Released exosomes are targeted to glial
cells, other neurons or the same neuron as well [69]. On the
one hand, the neuron-derived exosomes help, inter alia, to
communicate among neurons and oligodendrocytes resulting
in myelination (Fig. 2b). On the other hand, oligodendrocyte-
derived exosomes are endocytosed by neurons. Taken togeth-
er, neuronal activity influences the cargo transfer from
oligodendrocyte-derived exosomes to neurons. This suggests
that neuronal activity has a regulatory function regarding
receiving glial-derived components via the exosomes [65,
67, 70, 71].
Besides its function as a pure molecule transmission sys-
tem, microglia-derived (resident macrophages in the CNS
[72]) exosomes contain an intact metabolic pathway with all
the enzymes necessary for anaerobic glycolysis/lactate pro-
duction. In this way, microglia-derived exosomes can deliver
lactate to neurons, which support the energy balance during
synaptic activity. It is shown that these exosomes also contain
functionally active CD13. CD13 is able to catabolise neuro-
peptides (i.e. methionin- and leucine-enkephalin), preventing
the enkephalin-mediated cAMP decrease (Fig. 2b) [73].
Oligodendrocytes are a subclass of macroglia and support
neurons by producing neurotropic factors [74]. They are re-
sponsible for myelin forming, which includes an extremely
high membrane synthesis capacity. To remove excess mem-
brane, oligodendrocytes release part of the membrane in the
form of exosomes. It is proposed that microglia take up these
exosomes by macropinocytosis. This process directs the in-
coming cargo away from compartments with pro-
inflammatory receptors. Consequently, the antigen-
presenting function of microglia is infiltrated for the proteins
taken up via the exosomes. Due to the constitutive
macropinocytosis clearance of exosomes by (perhaps a spe-
cific subset of) microglia, these systems provide an immuno-
logically silent clearance of oligodendroglia membrane and
myelin proteins [75]. A balance in myelin synthesis is also
ensured by the level of proteolipid protein (PLP). PLP can be
packaged into exosomes whose release is regulated by cyto-
solic Ca2+ (Fig. 2b) [76].
Mast cells are effector cells of the innate immune system
and resident in most tissues characteristically surrounding the
blood vessels and nerves [77]. They are especially prominent
in tissues in close contact with the outside environment such
as the skin, mucosa of the lungs and the digestive tract. Like
macrophages, they are resident in the brains of many species.
They enter the CNS during development via penetrating the
blood vessels with which they remain associated [78]. In the
brain, almost 97 % of mast cells lie on the abluminal side of
the blood vessels [79]. Like lymphoblasts, mast cells can
move through the normal brain even in the absence of inflam-
mation, with rapid entry mediated via the BBB passage [80].
Because brain mast cell-derived exosomes can, as mentioned,
pass the BBB, they can present the CNS antigens to the
immune system outside of the CNS. It is known that mast
cell-derived exosomes activate B and T cells (Fig. 2c).
Potentially, mast cell-derived exosomes also induce matura-
tion and activation of DCs due to cross presentation of anti-
gens to T cells [71]. It was also observed that exogenous
antigens in mast cell-derived exosomes are both in naïve and
in processed form [71]. Mast cell-derived exosomes often
carry two heat shock proteins (hsp60 and hsp70), which are
known for their adjuvant activity. Therefore, even in the
absence of conventional adjuvants, they are highly efficient
in inducing an antibody response in vivo.
Exosomes Involved in Neurological Diseases
Besides the biological roles in the CNS outlined above, the
appearance of specific exosomes correlate with a number of
known neurological diseases such as Huntington’s disease
(HD), Parkinson’s disease (PD), AD, amyelotrophic lateral
sclerosis (ALS) and MS (Table 2). Various numbers of neu-
rological diseases such as HD, PD, ALS and AD are associ-
ated with the spread of a specific misfolded protein via the
exosome within the CNS [131].
HD is caused by CAG trinucleotide repeat expansion in the
huntingtin gene (Htt) leading to altered histone acetylation and
formation of mutant Htt [132]. MVBs in neurons have been
shown to contain Htt protein aggregates, and the pathology of
Table 2 PubMed publications for selected neurological diseases (18th
August 2014)
Search term NLM References PMC
Exosome 2908 7675
Alzheimer/AD and exosome 20 [81–100] 432
Multiple sclerosis/MS and exosome 8 [101–108] 601
Parkinson/PD and exosome 8 [109–116] 223
Huntington/HD and exosome 4 [113, 117–119] 115
Traumatic brain injury and exosome 4 [120–123] 118
Neuroinflammation and exosome 2 [124, 125] 190
Multiple system atrophy and exosome 2 [126, 127] 62
Amyotrophic lateral sclerosis/ALS
and exosome
4 [103, 128–130] 195
NLM National Library of Medicine, PMC PubMed Central
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HD is closely tied to the MVB function of recycling and
releasing these proteins via the exosomes [64]. A therapeutic
approach towards HD is the decrease of mutated Htt expres-
sion via small RNA carried and delivered by exosomes.
Theoretically, developed exosomes carrying small RNA can
pass the BBB and facilitate the inhibition of mutated Htt
expression.
PD is one of the most common neurodegenerative diseases
among people over 50 years old. PD is characterised by
degeneration of dopaminergic neurons in the substantia nigra
pars compact and the presence of Lewy bodies, primarily
composed of fibrillar α-synuclein (α-Syn) and ubiquitinated
proteins [133]. Exosomes released from injured neurons con-
tain α-Syn and are involved in the progress of PD by trans-
ferring the α-Syn to other neurons [109]. It was also reported
that α-Syn can induce the release of exosomes frommicroglia
cells [134]. These MHC II and membrane-bound tumour
necrosis factor-α (TNF-α) containing exosomes can induce
apoptosis. Therefore, it is proposed that exosomes can be
mediators of α-Syn-induced neurodegeneration in PD [134].
For AD, it has been reported that amyloid precursor protein
(APP) cleavage to β-amyloid occurs in early endosomes
followed by routing the β-amyloid to MVBs. In detail,
Rajendran et al. have detected APP and the β-amyloid pre-
cursor protein-cleaving enzyme (BACE) in early endosomes.
By immunogold labelling, they identified β-amyloid in
MVBs, which suggests that the secretion of β-amyloid pep-
tides can be associated with exosomes. In the brain sections of
AD patients, consequently, exosomal proteins (Pdcd6ip and
flotillin-1) were accumulated in plaques, whereas they were
almost absent in the brain sections of the control group. Based
on these data, it is proposed that exosomes could provide a
conducive environment for amyloidogenic fibril formation,
and subsequently, exosomes play a role in the pathogenesis
of AD [6, 135, 136].
ALS is a neurological motor neuron disease in which
specific motor neurons in the brainstem, cortex and spinal
cord are degenerated. Although the mechanisms involved
are largely still unknown, in recent years, it has been shown
that ALS is a non-cell-autonomous disease that implies the
interaction between motor neurons and glial cells. In a mouse
model, Basso et al. [137] have shown that on the one hand the
overexpression of a mutated copper-zinc superoxide dismut-
ase 1 (SOD1) in primary astrocytes is linked to a general
reduction of total amount of secreted proteins. On the other
hand, the group could observe an increase in the level of a
selected number of proteins known to be released by
exosomes [138]. Both, the cultivation together with astrocytes
expressing the mutated SOD1 and the cultivation together
with exosomes derived from these transgenic astrocytes, were
sufficient to induce motor neuron death in vitro. A concentra-
tion dependency could be shown by the fact that the motor
neuron viability decreased with increased concentrations of
the exosomes, which instead did not affect the neuron viabil-
ity. In contrast, exosome preparations from astrocytes express-
ing the unmutated SOD1 did not have an influence on the
motor neuron viability although the mutated/unmutated
SOD1 was taken up by the motor neuron cells in both cases.
At least in the mutant SOD1-linked experimental model, the
toxic factor produced and released via the exosomes by astro-
cytes mediates motor neuron death. That these findings may
be relevant in vivo is corroborated by the fact that astrocyte-
derived exosomes have been recently reported in rat cerebro-
spinal fluid [139]. The toxicity of astrocytes isolated from
postmortem tissue from ALS patients to motor neurons and
the involvement of SOD1 shown byHaidet-Philips et al. [140]
support the ALS model.
MS is a demyelinating disease featuring axonal injury
[141]. An increasing number of publications reveal the in-
volvement of exosomes in the pathogenesis of MS. Exosomes
play a pathological role by propagation of inflammation me-
diating the disruption of the BBB. Microglia-derived
exosomes carry interleukin-1β (IL-1β) and MHC II and,
therefore, support the spread of neuroinflammation [142].
Inflammation mediates the BBB disruption via the release of
cytokines (e.g. interferon-γ (IFN-γ), TNF-α, IL-1β) [143], as
well as the release of metalloproteinase-containing exosomes
from surrounding cells (e.g. astrocytes) [144]. Cytokines, such
as IFN-γ, can change the architectural organisation of tight
and adherens junctions between cerebral endothelial cells of
BBB [145]. Cytokines such as TNF-α and IL-1β promote the
disruption of BBB via expression of inducible nitric oxide
synthase [146]. In addition, metalloproteinases, which get
delivered via exosomes, disrupt the BBB by degrading tight
junction and basal lamina proteins, thereby leading to BBB
leakage [147]. An untightened BBB enables leukocytes to
migrate into the CNS [148].
Exosomes not only directly influence the pathology of MS
but also provide information regarding the developmental
status of this disease. These attributes favoured them as a
therapeutic target as well as a diagnostic tool [149]. As an
example, plasma of MS patients in the exacerbation phase
contained 2.85-fold more CD31 (endothelial marker involved
in acute injury) in exosomes than healthy control patients. The
CD51 (marker for chronic injury of endothelium) content
detected in plasma exosomes stays elevated in both exacerba-
tion and remission phases. These examples mention that
exosomes isolated from MS patients can provide information
regarding the disease state [142, 148].
Other studies suggest the application of exosomes as an
agent to transport immune-suppressive components through
the BBB. For instance, MSC-derived exosomes can decrease
inflammation and stop the demyelination of axons. ForMSCs,
an immune-suppressive functionality and assistance in neuro-
nal repair is observed. Previously, MSCs were proposed as a
treatment for autoimmune diseases such as MS [150–152]. In
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recent times, it was proposed that the application of MSC-
derived exosomes could mediate the same effects [153].
Along with using pure MSC-derived exosomes, serum-
isolated exosomes containing miR-219 can also stop demye-
lination and the progress of MS in mice. As a matter of fact,
one interesting and almost recent finding was the potential
remyelination effect of MSC-derived exosomes. Based on the
study of Pusic et al. [60, 154], the application of IFN-γ-
stimulated DC-derived exosomes containing a high level of
miR-219 results in an increased remyelination of lysolecithin-
induced demyelinated brain slice cultures. As supported by
other studies, miR-219 has a major impact in differentiation of
oligodendritic precursor cells and improvement of
remyelination [154, 155]. In a later study, Pusic et al. [155]
also showed that the application of serum-isolated exosomes
from young rats improve remyelination in old ones. This
could not be observed by using serum-isolated exosomes from
old rats. However, the application of serum-isolated exosomes
of environmental enriched (volitionally increased intellectual,
social and physical activity) old rats improved the
remyelination in old animals. In contrast to the exosomes
derived from the old rats, both the exosomes from the young
rats and the exosomes from the old environmental enriched
rats contain miR-219, which is required for the production of
myelinating oligodendrocytes [155]. In that study, it was also
shown that the nasal delivery of the serum-isolated exosomes
from young rats resulted in remyelination and, therefore,
provided evidence for the potential therapeutic effects in the
treatment of MS patients [59, 155].
For several CNS cell types, it was observed that exosomes
play a crucial role in many biological processes. In addition,
exosomes were studied concerning their role in several neu-
rodegenerative and neurological diseases. These examinations
offer promising key approaches towards diagnoses and treat-
ments of this group of diseases. In this context, the ability of
the exosomes to pass the BBB is an essential feature.
Exosomes as a Tool for Diagnosis and Therapy
Exosomes are considered as a breakthrough in the diagnosis
and as a potential therapeutic delivery system. They are sug-
gested for diagnostic applications as they are isolable from all
biological fluids and, therefore, provide a non/least invasive
diagnostic method [156]. The majority of miRNA detectable
in serum and saliva is concentrated in exosomes [157], where
they are protected against RNases [158]. RNA and protein
profiles of circulating exosomes can be correlated to specific
diseases. As an example, serum-isolated exosomes from pros-
tate cancer patients are selectively enriched with miR-141 in
comparison to healthy controls [158]. Such diagnostic appli-
cations of exosomes were also described for colorectal cancer
[159], ovarian cancer [160] and melanoma [161].
The diagnostic application of exosomes is not confined
to the detection of miRNA. It was observed that the protein
profile of exosomes isolated from the urine of patients with
bladder cancer is different from the normal controls [162].
The detection of epidermal growth factor receptor variant
III protein (EGFRvIII), a variant III EGFR deletion mutant
missing 267 amino acids, plays a key role in gliablastoma
diagnosis. Conventionally, biopsies are removed from the
brain to check for EGFRvIII protein. The extraction of a
biopsy from the brain is a complex invasive surgery. The
same results can be obtained in a simple, much less inva-
sive manner by the exosome screening for EGFRvIII pro-
tein, which is present in exosomes isolated from these
patients. Therefore, their use can be a replacement for
biopsy and, accordingly, extensively beneficial to the pa-
tients [163, 164].
Taken together, RNA and protein isolated from exosomes
of cancer patients start to be used as diagnostic tools.
Furthermore, analysis of exosomes makes it possible to cate-
gorise patients into different tumour risk classes enabling a
more proper treatment towards the malignancy of tumours
[165].
However, there are also some points that should be consid-
ered before relying thoroughly on the data obtained from
exosomes in terms of diagnosis.
& Exosomes from different cell origins potentially have
different compositions in their membrane, which affect
their susceptibility to lysis. Different degrees of efficacy
in lysis and isolation of the containing material could
result in an alternative and probably false assumption of
the result [166].
& Although up to now many studies have reported the
high accurate association of some biomarkers with
specific diseases in a large number of patients, the
results of these studies do not match or, in some cases,
even do not overlap. This discrepancy can be ex-
plained by several facts: (i) The most often used
technique for diagnostic and assessing the nucleic acid
content of exosomes is microarray technology; pub-
lished data are often incomplete or incompletely an-
notated and therefore hard to reproduce [167]. (ii) As
already mentioned, there are varieties of isolation
techniques that can greatly influence the relative
amount of the specific exosome cargo.
& In addition, the technology is rapidly evolving, but there is
not yet a clear-cut unity for the analysis of large-scale
profiles of small RNAs in exosomes [166].
& One last point is the probable medication. The source of
exosomes is mainly from patients who have been most
probably on medication before exosome isolation. The
medication can alter some pathways and affect the mole-
cules of interest.
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A biomarker for clinical setting should be sensitive and
specific for any individual case with a clear-cut definition. As
it is not always possible to compare the patient with a specific
control group, more studies and precise analyses (e.g. by next
generation sequencing) are necessary to make exosomes rou-
tinely approachable for diagnosis means.
Exosomes are also suggested as a therapeutic delivery
system. By their homing characteristic, they can deliver their
cargo to specific targets over a long distance. Exosomes can
also be used to deliver interfering RNA (siRNA) or pharma-
ceutically active substances [23, 168, 169]. It was shown that
exosomes can be loaded with a specific cargo such as inter-
ference RNA (iRNA) and subsequently injected intravenously
into mice. These injected exosomes were detected just in the
target cells and no non-specific uptake was reported [168]. In
the meantime, several groups could prevent tumour develop-
ment—or suppress inflammatory responses in autoimmune
patients—by using different sources of exosomes such as
plasmacytoma cell-derived exosomes or exosomes derived
from IL-10-treated DCs [156, 170]. In addition, it was shown
that mouse exosome containing mRNA can be taken up by
human cells, which consequently express the mouse proteins
[10]. This observation potentially opens up a wide range of
therapeutic aspects, such as treatment by transporting a spe-
cific protein to recipient cells lacking this specific protein, or a
protein with a specific regulatory function. In addition to
proteins, the potential transport of molecules could also in-
clude, e.g. mRNAs, miRNAs, iRNAs and drugs.
Overall, an exosome-based delivery system has particular
benefits such as (i) specificity, as the exosomes deliver their
cargo to a specific target; (ii) safety, as self-derived exosomes
promote no undesired immunogenicity; and (iii) stability, not
only the exosomes itself as nanostructures circulating in the
blood were reported stable but also the content of exosomes
are protected from RNases and proteases and, therefore, can
be delivered in an intact form to the target cell [23]. Despite
these benefits, there are some, until now, unsolved problems
such as identifying and purifying a single subpopulation of
endogenous cell-specific exosomes. Also, some findings are
disservices to the clinical application of the isolated exosome:
& Exosomes possibly play a major role in the replication
and propagation of transmissible pathogens [156]. This
means that exosomes, which are derived from bacteria-
or virus-infected cells, may contain factors such as
pathogen-derived antigens or cytokines that activate a
pro-inflammatory pathway. Pathogens also release ves-
icles that fuse with the plasma membrane of their target
cells and release their contents into the cytosol of the
recipient cell [8]. In addition, it is known that HIV uses
the exosome pathway for its assembly and release
[171]. Also, prion proteins mediate their intercellular
transfer via exosomes [172].
& Exosomes have a diverse effect on health and diseases that
are not thoroughly understood and controllable. Even
though some exosomes can prevent tumour development,
others provide a communication system between tumour
cells and the surrounding tissues. In fact, exosomes are
suggested as a nanodelivery system, which functions for
tumour-associated proteins and, consequently, Cav-1-
bearing exosomes. It is suggested that exosomes transfer
Cav-1 to less aggressive cells and promote their invasive
activity [173].
Considering these points, it was suggested to use exosome
mimetic structures as an artificial treatment. Exosomemimetic
delivery systems would be more controllable and scalable for
clinical settings, and they can deliver anti-tumour drugs to the
target cells [23]. Liposomes with a bilayer phospholipid and
size of almost 100 nm can carry a variety of proteins and
nucleic acids as well as pharmaceutically active substances.
Such exosome mimetic structures also need specific targeting
molecules. Thus, more information regarding targeting and
releasing of exosomes is needed [174]. Currently, liposomal
transport of drug molecules is under clinical trial [175], and
lately, Gomez-Cabrero et al. developed specifically targeted
liposomal nanoparticles and safely delivered doxorubicin (a
chemotherapeutic drug commonly used to treat breast cancer)
to a tumour microenvironment [176].
Conclusion
Exosomes are small vesicles, which are formed by inward
budding of MVBs and released via the plasma membrane.
They are secreted by most if not all cells and can easily be
isolated from biological fluids. These bilayer phospholipids
can deliver mRNAs, miRNAs, proteins and, in some cases,
DNAs. It was observed that the contents of exosomes are not
entirely coincidently packed, but a selective process that con-
ducts this loading. Due to normal biological processes in the
cell, exosomal transport systems help cells to regulate other
cells in distance and communicate with them. Cancer cells and
malignant cells use this system to promote their invasive
activity and suppress the immune system to act upon them.
Exosomes are considered a great diagnostic tool as they can
be detected in biological fluids, they are very stable and their
contents are protected. In addition, they are considered inmany
clinical studies as a delivery system to transport RNA, protein
and drug molecules, especially as they can pass the BBB.
Nonetheless, there are also some not yet overcome disad-
vantages in using them for clinical terms. Their role is not
completely understood, and in some cases, they can even
activate pro-inflammatory pathways or suppress immune re-
actions. Thus, the use of exosome mimetic structures is
favoured to target recipient cells and deliver pharmaceutically
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active substances. For developing such structures, a lot of
topics stay open and need to be explored more in detail: (i)
precise understanding of exosome biogenesis and targeting,
(ii) providing a reliable method to target the exosomes in vivo
and in vitro, (iii) isolation of a pure class of extracellular
vesicles, (iv) clarification of the regulatory function of
exosomes and (v) the effect of introducing excessive amounts
of exosomes in an in vivo system. Besides, by improvement of
the isolation techniques and detection of exosomes, we may
rely more on these structures. Primary studies have also re-
ported the successful delivery of chemotherapeutic drug-
loaded exosome mimetic microvesicles to tumour tissue
in vivo and in vitro [177].
Altogether, exosomes appear to be a specific and stable
intercellular communication system, which can be used to obtain
information more comfortably and less aggressively from inner
organs and systems. Also, exosome mimetic structures can be
designed to securely and specifically control the interactions
between cells. For these aims, there is a lot to investigate regard-
ing this fascinating delivery and target system.
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Take Home Message:
Exosomes are extracellular vesicles, which provide a long distance com-
munication system among different cells. A number of known molecules
such as RNA and protein can be the cargo of exosomes designated to
specific target cells. A summary of the current knowledge of small
vesicles, the biogenesis, targeting, cargo and detection of exosomes is
given followed by the role of exosomes in physiological functions in the
CNS. Exosomes can pass through the BBB and enhance the communi-
cation of the CNSwith the rest of the body. This fact favours exosomes as
an important tool for new approaches in the diagnoses and treatments of
many neurological diseases, which are discussed. Exosomes are the key
to the future diagnosis of many neurological diseases, which current
analyses and further investigations are mostly only possible—if at
all—by highly invasive methods.Moreover, exosome-like structures with
the same features of targeting can apply the desired cargo to the target
cells in order to induce or inhibit a desired reaction.
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